Shots:

• The P-III SELECT-PsA 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease-modifying anti-rheumatic drugs (bDMARDs)
• The P-III SELECT-PsA 2 study results: @12wks. patients achieved ACR20 (57%/64% vs 24%)- ACR 50(32%/38% vs 5%)- ACR 70 (9%/17% vs 0.5%); @16wks. patients achieved PASI 75 (52%/57% vs 16%); @24wks. patients achieved minimal disease activity (25%/29% vs 3%); safety profile was consistent with the previous studies with no new safety risks detected
• RINVOQ is a selective and reversible JAK inhibitor- developed by Amgen- currently being studied for once-daily therapy in psoriatic arthritis and multiple immune-mediated diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image:  AbbVie